.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The SAFE trial compared 4% albumin with normal saline for intravascular volume resuscitation in almost 7,000 critically ill adults. Mortality at 28 days was similar between the two groups, and there were no significant differences in ICU or hospital length of stay, duration of mechanical ventilation or use of renal-replacement therapy. The study provided high-quality evidence that, across a broad ICU population, albumin did not confer an overall survival advantage over saline. SAFE is important because fluid choice is one of the most frequent decisions in critical care, yet physiologic reasoning does not always translate into better outcomes. The trial also highlights that effects can vary across subgroups: subsequent analyses suggested that patients with traumatic brain injury may be harmed by albumin-based resuscitation, illustrating why “equivalence” in a heterogeneous ICU population does not mean equivalence for every condition. For bedside practice, crystalloid remains the default resuscitation fluid for many patients, with albumin considered selectively when there is a specific clinical rationale. The larger lesson is that fluid therapy should be treated like any other drug: indication, dose, patient phenotype and cumulative exposure all matter.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The SAFE trial compared 4% albumin with normal saline for intravascular volume resuscitation in almost 7,000 critically ill adults. Mortality at 28 days was similar between the two groups, and there were no significant differences in ICU or hospital length of stay, duration of mechanical ventilation or use of renal-replacement therapy. The study provided high-quality evidence that, across a broad ICU population, albumin did not confer an overall survival advantage over saline. SAFE is important because fluid choice is one of the most frequent decisions in critical care, yet physiologic reasoning does not always translate into better outcomes. The trial also highlights that effects can vary across subgroups: subsequent analyses suggested that patients with traumatic brain injury may be harmed by albumin-based resuscitation, illustrating why “equivalence” in a heterogeneous ICU population does not mean equivalence for every condition. For bedside practice, crystalloid remains the default resuscitation fluid for many patients, with albumin considered selectively when there is a specific clinical rationale. The larger lesson is that fluid therapy should be treated like any other drug: indication, dose, patient phenotype and cumulative exposure all matter.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
